Averin Capital
Overview
Averin Capital is a New York-based early-stage venture firm (240 West 40th Street, Suite 205) that invests where breakthrough technology is changing human health. It was previously called Bedford Bridge and rebranded to Averin on 2025-05-05. The firm was co-founded in 2024 by David Berry, MD PhD (formerly General Partner at Flagship Pioneering, founder and CEO of Valo Health) and Eric Berry (founder and CEO of TripleLift, which sold a majority stake to Vista Equity Partners for over $1.4B). The site says the team has founded or launched more than 30 companies, and that 22 companies worth over $1B were helped build, lead, or back by members of the Averin team.
Investment Thesis
Averin organizes its thesis into five areas: Foundational Science (biology, quantum computing, materials science and space research turned into research tools, diagnostics, and drug development), Physical AI (robotics, sensors, and intelligent medical devices that help clinicians see more and work with more precision), Care Delivery (changing how care is organized, delivered, and paid for, with outcomes and a sustainable business model together), Healthcare Infrastructure (clinical trials, manufacturing, data exchange, and payments), and Human Performance (preserving and restoring physical and cognitive function and addressing the biology of aging). AI is described as a capability that runs across areas, not a requirement for every investment. Published essays show the working views: AI-saved physician time and who captures the value, the malpractice-underwriting gap for clinical AI, continuous observation replacing the annual primary care visit, drug abundance through AI and automation, and state-level markets for unapproved treatments.
Stage, Check Size, Lead Tendency
According to the firm's own FAQ, Averin invests from pre-seed through later stages and also creates companies. Typical initial investments range from $500,000 to $10 million, and Averin sometimes leads rounds. Lead tendency is therefore best read as both. Companies founded with Averin (xPharma AI in 2025 and an unnamed 2026 stealth company led by Nazim Bouatta) show a company-creation track alongside conventional venture investing. Fund size and AUM are not published on the site, so AUM is left empty.
Geography
Based in New York, with partners in New York and Boston. The firm says it invests in companies in the United States, Europe, and Asia.
Portfolio Highlights
The companies page lists nine named companies plus one unnamed stealth company: Biolinq (wearable glucose sensing, partnered 2024), CandidPro (doctor-directed clear aligners, 2023), Commons Clinic (musculoskeletal care, 2026), Freenome (early cancer detection, now public on Nasdaq as FRNM, 2023), Hologen AI (AI models over imaging, genetics, labs and records, 2025), Mendaera (handheld robotics and ultrasound needle guidance, 2026), Pine Park Health (value-based primary care in senior living, 2025), Salma Health (coordinated brain and mental health care, 2024), and xPharma AI (AI-structured drug asset profiles and data rooms, founded with Averin in 2025). The mix spans diagnostics, devices and robotics, care delivery, and AI for drug development.
Team and Decision Process
Managing Partners David Berry and Eric Berry lead the firm, joined by Partners Tristan Hunt, MD and Jeffrey Low, MD (announced as partners 2025-01-08), Tomer Zitelny, and Alex Lau (Partner and COO), plus Investor Ben Tomaszewski. The firm describes evaluating technical, scientific, commercial, and company-building questions together, which points to a partnership process. An advisory board includes Steve Bolze (former CEO GE Healthcare), Mikael Dolsten (former CSO Pfizer, joined 2026-06-30), Roland Diggelmann (former CEO Roche Diagnostics), Thad Johnson (former CLO UnitedHealth), David Shulkin (former US Secretary of Veterans Affairs), Ulrik Schulze, JP Millon, and Todd Ruppert.
Founder Preferences
The firm positions itself as operators helping operators: candid, forward-looking board partners who engage when their experience helps and step back when it does not. Founder testimonials (CandidPro, Osler Diagnostics) stress strategic and operational help, investor introductions, and boardroom experience. Expect a preference for founders tackling hard problems in healthcare with real scientific or clinical substance, and teams that value hands-on operating support.
Recent Activity
An affiliated blank-check company, Averin Capital Acquisition Corp. (Nasdaq: ACAA), priced a $250M IPO in February 2026. Portfolio activity in 2026 includes new partnerships with Commons Clinic and Mendaera, and a new stealth company. The firm publishes steadily: podcasts and essays nearly every week through October 2026. Fund status is read as actively deploying, though fund size is undisclosed.